Clinical trial
A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of…
NCT00350090 · Ortho Biotech Products, L.P., Industry · Terminated
Key facts
| NCT number | NCT00350090 |
|---|---|
| Title | A Study to Assess the Response Rate of PROCRIT (Epoetin Alfa) Given at a Dose of 40,000 Units Once a Week to Cancer Patients With Anemia Who Are Not Receiving Chemotherapy. |
| Official title | A Pilot Study to Evaluate the Response Rate of PROCRIT (Epoetin Alfa) at 40,000 Units Once Weekly in Anemic Cancer Patients Not Receiving Chemotherapy |
| Lead sponsor | Ortho Biotech Products, L.P., Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Anemia, Neoplasms |
| Intervention type | Drug |
| Interventions | Epoetin Alfa |
| Enrollment | 98 |
| Start date | Sep 1, 2002 |
| Completion | Mar 1, 2004 |
| First posted | Jul 10, 2006 |
| Last update posted | May 19, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: